Abstract

The guanylate cyclase-C receptor agonist linaclotide (Linzess – Abbvie/Ironwood) was first approved by the FDA in 2012 for treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Treatment Of Chronic Idiopathic Constipation
  • Irritable Bowel Syndrome
  • Constipation In Adults
  • Treatment Of Irritable Bowel Syndrome
  • Treatment Of Constipation
    • + Show 5 more

Create a personalized feed of these topics

Get Started

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Lubiprostone for constipation and irritable bowel syndrome with constipation
  • Expert Review of Gastroenterology & Hepatology
  • Dec 1, 2008
Relevant
Not Relevant
Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome
  • Mayo Clinic Proceedings
  • Apr 1, 2016
Relevant
Not Relevant
Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.
  • The American journal of gastroenterology
  • Apr 1, 2022
Relevant
Not Relevant
Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation.
  • Neurogastroenterology and motility
  • Jun 18, 2023
Relevant
Not Relevant
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation
  • Advances in Therapy
  • May 14, 2009
Relevant
Not Relevant
Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain
  • Trends in Pharmacological Sciences
  • Feb 1, 2022
Relevant
Not Relevant
Treatment of Idiopathic Chronic Constipation and Irritable Bowel Syndrome with Constipation: What Role for Lubiprostone?
  • Clinical Medicine Insights: Therapeutics
  • Aug 17, 2010
Relevant
Not Relevant
Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome
  • Therapeutic Advances in Chronic Disease
  • Aug 1, 2013
Relevant
Not Relevant
Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome
  • Advances in Therapy
  • Feb 20, 2013
Relevant
Not Relevant
Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older
  • Clinical Therapeutics
  • Jul 1, 2020
Relevant
Not Relevant
M1706 Discontinuation of Lubiprostone Treatment for Irritable Bowel Syndrome with Constipation Is Not Associated with Symptom Increase or Recurrence: Results from a Randomized Withdrawal Study
  • Gastroenterology
  • Apr 1, 2008
Relevant
Not Relevant
Biofeedback for treatment of chronic idiopathic constipation in adults
  • Cochrane Database of Systematic Reviews
  • Mar 26, 2014
Relevant
Not Relevant
Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome
  • Expert Opinion on Drug Safety
  • Sep 1, 2012
Relevant
Not Relevant
Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis
  • American Journal of Gastroenterology
  • Mar 1, 2018
Relevant
Not Relevant
Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome
  • The American Journal of Medicine
  • May 1, 2019
Relevant
Not Relevant
READ MORE FROM

The Medical letter on drugs and therapeutics

Sulbactam/durlobactam (Xacduro) for Acinetobacter pneumonia.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Shockwave therapy for erectile dysfunction.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
In brief: GI effects of GLP-1 receptor agonists.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Ritlecitinib (Litfulo) for severe alopecia areata.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Addendum.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Etrasimod (Velsipity) for ulcerative colitis.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
COVID-19 update: New Novavax vaccine formulation for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Correction.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
In brief: Empagliflozin (Jardiance) for chronic kidney disease.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Antiviral drugs for influenza for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant